<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for <z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond Syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Among 71 SDS patients included in the French Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> Registry, 10 received HSCT between 1987 and 2004 in five institutions </plain></SENT>
<SENT sid="2" pm="."><plain>The indications were <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> in five cases, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0001909'>leukemia</z:hpo> in five cases </plain></SENT>
<SENT sid="3" pm="."><plain>The median follow-up of patients who survived without relapse is 6.9 years (3.1-16.8 years) </plain></SENT>
<SENT sid="4" pm="."><plain>The conditioning regimen consisted of a <z:chebi fb="0" ids="28901">busulfan</z:chebi>-<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> combination (n=6) or total body irradiation plus chemotherapy (n=4) </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients received stem cells from unrelated donors and four from identical siblings </plain></SENT>
<SENT sid="6" pm="."><plain>Engraftment was complete in eight patients and unassessable in two patients </plain></SENT>
<SENT sid="7" pm="."><plain>These latter two patients died of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> 32 and 36 days after HSCT, with grade IV <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> and multiorgan dysfunction </plain></SENT>
<SENT sid="8" pm="."><plain>A third patient died from an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> syndrome 17 months after HSCT with progressive granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>One patient had an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> relapse 4 months after HSCT and died 10 months later </plain></SENT>
<SENT sid="10" pm="."><plain>The overall 5-year event-free survival rate is 60+/-15% </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that HSCT is feasible for patients with <z:chebi fb="26" ids="8984">SDS</z:chebi> who develop <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> or <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
</text></document>